Absci (ABSI) Net Equity Issued and Repurchased (2020 - 2026)
Absci (ABSI) posted Net Equity Issued and Repurchased of $8.0 million for Q1 2026, up 127.41% sequentially from $3.5 million in Q4 2025, and down 80.91% YoY from $41.7 million in Q1 2025.
Powered by 
Analysis
Absci (ABSI) Net Equity Issued and Repurchased (2020 - 2026) Analysis & Trends
Absci has reported Net Equity Issued and Repurchased for 7 years, with the latest figure at $8.0 million in Q1 2026.
- Quarterly Net Equity Issued and Repurchased fell 80.91% year-over-year to $8.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $72.1 million (up 66.67% YoY) and the FY2025 annual result came in at $105.8 million, up 28.44% from the prior year.
- Net Equity Issued and Repurchased improved to $8.0 million in Q1 2026 per ABSI's latest filing, from $3.5 million in the prior quarter.
- Over five years, Net Equity Issued and Repurchased peaked at $80.8 million in Q1 2024 and troughed at -$2.2 million in Q4 2024.
- A 5-year average of $12.3 million and a median of $304500.0 in 2023 frame the typical range for Net Equity Issued and Repurchased.
- The sharpest annual moves came in 2023 and 2024: Net Equity Issued and Repurchased plunged 1198.48% in 2023, then surged 35195.63% in 2024.
- Over 5 years, Net Equity Issued and Repurchased stood at $66000.0 in 2022, then slumped by 1198.48% to -$725000.0 in 2023, then plunged by 204.69% to -$2.2 million in 2024, then soared by 258.4% to $3.5 million in 2025, then surged by 127.41% to $8.0 million in 2026.
- According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered $8.0 million, $3.5 million, and $60.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | 141.90 Mn |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | - |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | - |
| 10 | Absci | 1.38 Bn | 1.18 Bn | - | 98.14 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 98.14 Mn |
| Mar 31, 2026 | 7.96 Mn |
| Dec 31, 2025 | 3.50 Mn |
| Sep 30, 2025 | 60.65 Mn |
| Mar 31, 2025 | 41.69 Mn |
| Dec 31, 2024 | -2.21 Mn |
| Sep 30, 2024 | 1.39 Mn |
| Jun 30, 2024 | 2.39 Mn |
| Mar 31, 2024 | 80.83 Mn |
| Dec 31, 2023 | 137,000.00 |
| Sep 30, 2023 | 380,000.00 |
| Jun 30, 2023 | 116,000.00 |
| Mar 31, 2023 | 229,000.00 |
| Dec 31, 2022 | 66,000.00 |
| Sep 30, 2022 | 162,000.00 |
| Jun 30, 2022 | 215,000.00 |
| Mar 31, 2022 | 213,000.00 |
| Dec 31, 2021 | 71,000.00 |
| Sep 30, 2021 | 205.38 Mn |
| Mar 31, 2021 | 4.94 Mn |